Opioid Generics Should Focus On Abuse-Deterrent Performance, Not Technology, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Inability to convert OxyContin into an injectable form was an important factor in FDA’s decision to allow an abuse-deterrent claim in labeling, CDER’s Throckmorton says during the first of a series of hearings planned by the Energy and Commerce Health Subcommittee to examine prescription drug abuse.